1Life Healthcare, Inc. (NASDAQ:ONEM) to Post Q2 2021 Earnings of ($0.24) Per Share, William Blair Forecasts

1Life Healthcare, Inc. (NASDAQ:ONEM) – Equities researchers at William Blair decreased their Q2 2021 earnings estimates for 1Life Healthcare in a research report issued to clients and investors on Monday, June 7th. William Blair analyst R. Daniels now forecasts that the company will earn ($0.24) per share for the quarter, down from their previous forecast of ($0.09). William Blair also issued estimates for 1Life Healthcare’s Q3 2021 earnings at ($0.22) EPS, Q4 2021 earnings at ($0.27) EPS, FY2021 earnings at ($1.02) EPS, Q1 2022 earnings at ($0.14) EPS, Q2 2022 earnings at ($0.17) EPS, Q3 2022 earnings at ($0.18) EPS, Q4 2022 earnings at ($0.24) EPS and FY2022 earnings at ($0.73) EPS.

A number of other research firms have also issued reports on ONEM. Truist reduced their target price on 1Life Healthcare from $56.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, May 13th. Jefferies Financial Group started coverage on shares of 1Life Healthcare in a research note on Monday, May 3rd. They issued a “buy” rating and a $63.00 price target on the stock. Deutsche Bank Aktiengesellschaft dropped their price target on shares of 1Life Healthcare from $50.00 to $39.00 and set a “buy” rating on the stock in a research note on Wednesday. KeyCorp assumed coverage on shares of 1Life Healthcare in a research note on Friday, May 21st. They issued an “overweight” rating and a $41.00 price target on the stock. Finally, Zacks Investment Research raised shares of 1Life Healthcare from a “sell” rating to a “hold” rating in a research report on Thursday, February 25th. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $47.47.

ONEM opened at $33.97 on Thursday. The firm has a fifty day simple moving average of $38.78. The stock has a market capitalization of $4.67 billion, a price-to-earnings ratio of -47.18 and a beta of 1.26. 1Life Healthcare has a 12-month low of $25.40 and a 12-month high of $59.82. The company has a debt-to-equity ratio of 0.64, a current ratio of 5.53 and a quick ratio of 5.49.

1Life Healthcare (NASDAQ:ONEM) last released its earnings results on Tuesday, May 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.15). The business had revenue of $121.40 million during the quarter, compared to analysts’ expectations of $116.15 million. 1Life Healthcare had a negative net margin of 22.27% and a negative return on equity of 18.06%. 1Life Healthcare’s revenue for the quarter was up 54.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.40) EPS.

Several institutional investors have recently modified their holdings of the stock. HM Payson & Co. boosted its position in shares of 1Life Healthcare by 71.4% during the fourth quarter. HM Payson & Co. now owns 732 shares of the company’s stock worth $32,000 after purchasing an additional 305 shares in the last quarter. Dynamic Advisor Solutions LLC increased its stake in shares of 1Life Healthcare by 5.3% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 8,328 shares of the company’s stock worth $325,000 after purchasing an additional 422 shares during the last quarter. Valeo Financial Advisors LLC increased its stake in shares of 1Life Healthcare by 102.3% during the 1st quarter. Valeo Financial Advisors LLC now owns 866 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of 1Life Healthcare by 7.9% during the 1st quarter. Prudential Financial Inc. now owns 6,455 shares of the company’s stock worth $252,000 after purchasing an additional 470 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of 1Life Healthcare by 1.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,272 shares of the company’s stock worth $1,261,000 after purchasing an additional 497 shares during the last quarter. 83.93% of the stock is owned by institutional investors and hedge funds.

In other 1Life Healthcare news, General Counsel Lisa A. Mango sold 1,098 shares of the firm’s stock in a transaction dated Thursday, April 8th. The shares were sold at an average price of $42.03, for a total transaction of $46,148.94. Following the completion of the transaction, the general counsel now owns 81,265 shares in the company, valued at $3,415,567.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Lisa A. Mango sold 1,915 shares of 1Life Healthcare stock in a transaction that occurred on Monday, April 26th. The shares were sold at an average price of $42.15, for a total transaction of $80,717.25. Following the completion of the transaction, the general counsel now owns 81,667 shares of the company’s stock, valued at approximately $3,442,264.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 122,521 shares of company stock valued at $5,022,893.

About 1Life Healthcare

1Life Healthcare, Inc operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as employer sponsorship. Its membership model includes seamless access to digital health services paired with inviting in-office care routinely covered under health insurance programs.

Featured Story: New Google Finance Tool and Screening Stocks

Earnings History and Estimates for 1Life Healthcare (NASDAQ:ONEM)

Receive News & Ratings for 1Life Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 1Life Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.